# GeneCraft

Source: https://onco.cc/companies/genecraft/  
OnCo record `genecraft` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

GeneCraft is a Korean company testing a gene therapy, injected into the tumour, that restores a natural defence gene called RUNX3 to kill lung cancer cells driven by faulty KRAS.

## Summary

GeneCraft Inc., headquartered at Chungbuk National University in Cheongju with an R&D centre in Seoul, develops gene therapies built on the tumour-suppressor research of its founder and co-CEO Suk-Chul Bae on RUNX3. Its lead programme RX001 (AAV-hRUNX3), made on its Ubi-AAV platform, is designed to selectively kill KRAS-mutated cancer cells; a phase 1 dose-escalation study gives a single intratumoral injection to patients with advanced KRAS-mutant non-small cell lung cancer (NCT06934590). Its first registered cancer trial, NCT06934590, was posted on ClinicalTrials.gov in April 2025.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: GeneCraft Inc.
- HQ: Cheongju
- Type: biotech
- Website: https://www.genecraft.co.kr/

## Notes

- Company website read on 29 October 2026; it still describes the company as pre-clinical. Founding year not stated. No financing amounts read. OnCo has no technology record for AAV gene therapy, so no technology is linked.

## Sources

- Official website: https://www.genecraft.co.kr/
- ClinicalTrials.gov: phase 1 trial of RX001 (NCT06934590): https://clinicaltrials.gov/study/NCT06934590

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- targets: [KRAS](https://onco.cc/targets/kras/)

---
JSON: https://onco.cc/api/v1/entities/genecraft.json